Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Manufacturing
  • Novartis unveils North Carolina API plant as final piece of $23B US expansion
  • Manufacturing

Novartis unveils North Carolina API plant as final piece of $23B US expansion

BioSpace

The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites.

Read full story

pharminent May 1, 2026 (Last updated: May 1, 2026)

BioSpace

The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Amgen positions MariTide as potential ‘best monthly’ obesity drug
Next: Pfizer, Arvinas join SERD club with Veppanu approval

Related Stories

  • Manufacturing

pharminent June 17, 2026
  • Manufacturing

Eisai claims UK grant to expand manufacturing site

pharminent June 15, 2026
  • Manufacturing

FDA imposes import alert on Indian plant after inspectors flag GMP failings

pharminent June 12, 2026

You May Have Missed

  • News

pharminent June 22, 2026
sample_feature_2026-06-22
  • News

AbbVie to Acquire Apogee Therapeutics for Nearly $11 Billion in Immunology Bet

pharminent June 22, 2026
  • M&A / Deals

AbbVie climbs post-Allergan M&A peak with Apogee buy

pharminent June 22, 2026
  • M&A / Deals

Lilly bets up to $800M for BioArctic’s brain delivery tech

pharminent June 22, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.